What is Lifecore Biomedical's latest dividend and current dividend yield?

What were the key takeaways from Lifecore Biomedical’s earnings call?

What does Lifecore Biomedical do and what are its main business segments?

What were the key takeaways from Lifecore Biomedical's earnings call?

What is the market's earnings forecast for Lifecore Biomedical next quarter?

What is the revenue and EPS growth rate for Lifecore Biomedical year over year?

Did Lifecore Biomedical beat or miss consensus estimates last quarter?

What guidance did Lifecore Biomedical's management provide for the next earnings period?

- **Strategic Wins**: 9 new programs signed in 2025, including late-stage GLP-1 and Phase II dermatology deals, driving near-term momentum.
- **Operational Excellence**: 97% on-time delivery rate, successful FDA audit, and ERP system upgrade on track for Q1 2026.
- **Financial Resilience**: Met FY25 guidance with $128.9M revenue and $19.5M EBITDA, despite headwinds. Q4 2025 was strongest quarter of the year.
- **Growth Catalysts**: Expansion with key customer in 2027, late-stage pipeline commercialization, and U.S. pharma onshoring tailwinds.
- **Margin Outlook**: Gross margins to improve to low 30% range in 2026, with EBITDA margin target >25% unchanged.

**【CEO Summary Section】**
- **Strategic Progress in 2025**: Signed 9 new programs with 9 new customers, including a late-stage GLP-1 program and a Phase II dermatology program. Achieved 97% on-time delivery rate and met FY25 revenue and EBITDA guidance.
- **Growth Drivers**: 
  - **Existing Customers**: Expanded take-or-pay commitments with a key customer for 2027, including APAC market support.
  - **Late-Stage Pipeline**: Signed a 10-year commercial manufacturing agreement for an ophthalmic therapeutic, with PPQ batches underway.
  - **New Business**: Added 3 early-stage programs in respiratory and ophthalmology, plus a multimillion-dollar tech transfer with Humanetics.
- **Operational Enhancements**: 
  - ERP system go-live in Q1 2026 to improve efficiency and inventory control.
  - Workforce rightsizing reduced costs while increasing productivity.
  - FDA audit resulted in no major findings, reinforcing quality systems.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: 
  - Revenue: $36.4M (-4% YoY) due to lower CDMO development revenue, offset by +$4.1M HA manufacturing growth.
  - Gross Profit: $14M (-19% YoY) from CDMO mix shift.
  - Adjusted EBITDA: $9.1M (-12% YoY), but Q4 was strongest quarter of the year.
- **FY25 Full Year**: 
  - Revenue: $128.9M (+0.5% YoY), driven by HA manufacturing.
  - Adjusted EBITDA: $19.5M (-3% YoY), meeting guidance.
  - Net Loss: $38.7M due to legacy asset sales and stock-based comp.
- **2026 Transition Period Guidance (May 26 - Dec 31)**: 
  - Revenue: $74-76M
  - Adjusted EBITDA: $12-14M
  - Gross margins expected to improve to low 30% range.

**【Q&A Highlights】**
- **Customer Tariff Impact**: CEO dismisses 250% tariff talk as noise, but notes U.S. pharma manufacturing momentum is real. Lifecore sees pipeline growth from onshoring trends.
- **GLP-1 Program**: Collaboration with leading developer for 2029-2030 commercialization, terms confidential but strategically significant.
- **Margins Outlook**: CFO expects Q1 2026 gross margins ~30%, improving to low 30s by end of transition period. EBITDA margin target >25% remains unchanged.
- **ERP Implementation**: $600K-$1M investment, with go-live during planned shutdown in Q1 2026. Includes FDA/GMP validation and rollback plan.


Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript

- **Revenue Resilience**: Q3 revenue ($35.2M) aligned with guidance, supported by HA manufacturing growth and new customer signings (e.g., Nirsum, Humanetics).
- **Cost Efficiency**: SG&A down sequentially, with $2.2M legacy legal expenses. Live production monitoring and workforce optimization improved yields by 10%.
- **Strategic Momentum**: Late-stage pipeline programs (10+ for 2028 FDA approval) advanced, with one entering PPQ in late 2025. Four large pharma companies visited the facility, signaling partnership interest.
- **Cash Position**: $31M liquidity, expecting free cash flow neutrality in H2 from $10M filler proceeds and reduced expenses.

**【CEO Summary Section】**
- **Revenue Growth and Strategic Execution**: Q3 revenue of $35.2M remained on track with annual guidance, driven by HA manufacturing demand. The company signed six new customers, including Nirsum Laboratories and Humanetics, and advanced late-stage pipeline programs toward commercialization.
- **Operational Efficiency**: Implemented cost-saving measures such as reducing consulting fees, rebuilding the finance team, and adopting live production monitoring, resulting in improved production yields and reduced waste.
- **Customer Expansion**: Expanded partnerships with large multinationals, including a key program with a major pharmaceutical partner, and hosted four large multinationals at the facility during the quarter.

**【CFO Financial Commentary】**
- **Financial Performance**: Q3 net loss of $14.8M (-$0.47 EPS) vs. prior year's $15.6M ($0.42 EPS), impacted by one-time adjustments. Adjusted EBITDA of $5.7M (-$0.7M YoY) reflected gross profit declines offset by cost controls.
- **Cash Flow**: Positive cash flow from operations of $2M (excluding one-time expenses), with $31M liquidity. Expect free cash flow neutrality in the second half, supported by $10M remaining from filler sale proceeds.
- **Expense Management**: SG&A decreased sequentially, with $2.2M in legacy legal expenses. Stock-based compensation and consulting fees were reduced, positioning for further cost savings.

**【Q&A Highlights】**
- **Tariff Policy Impact**: CEO noted increased customer discussions on domestic manufacturing due to regulatory uncertainty, though no immediate quantitative impact.
- **Humanetics Contract**: A Phase 2 tech transfer project for BIO 300, reflecting expansion into new modalities and proximity to U.S. customers.
- **Cash Flow Outlook**: CFO expects second-half free cash flow improvement, driven by reduced legacy expenses and operational efficiency gains.
- **Customer Pipeline**: CEO highlighted 50+ pipeline opportunities, 30% with multinationals, with four large pharma companies visiting the facility in Q3.

Lifecore Biomedical (LFCR)-3 Apr 25-2025 Q3 Earnings call transcript

- **Revenue Growth**: Q2 revenue up 8% YoY to $32.6M, driven by CDMO and HA manufacturing.
- **Margin Expansion**: Gross margin improved due to price hikes and overhead absorption.
- **Strategic Wins**: Signed deal with Nirsum Labs for opioid treatment, doubling capacity with new filler.
- **Financial Strength**: $24.3M PIPE and debt restructuring boost liquidity.
- **Pipeline Momentum**: 10 late-stage programs and 50+ new opportunities targeting multinationals.
- **Customer Demand**: Pharma companies prioritizing late-stage site transfers and commercial manufacturing partners.


**【CEO Opening Remarks】**
- Q2 revenue grew 8% YoY to $32.6M, driven by CDMO and HA manufacturing growth.
- Gross margin improved due to price increases, favorable sales mix, and overhead absorption.
- Signed 2 new projects, including a deal with Nirsum Labs for opioid use disorder treatment.
- Installed a high-capacity 5-head filler, doubling revenue potential to $300M annually.
- Restructured leadership with Thomas Guldager (SVP Operations) and Jackie Klecker (EVP Quality), enhancing operational efficiency.

**【CFO Financial Highlights】**
- Q2 GAAP net loss: $6.6M (-32% YoY), impacted by $20.7M debt derivative adjustment in prior year.
- Adjusted EBITDA: $6.5M (+20% YoY), driven by $1.1M gross profit increase.
- 6M revenue: $57.3M (+5% YoY), with CDMO and HA manufacturing growth offsetting inventory write-downs.
- Completed $24.3M PIPE financing and amended BMO credit facility, strengthening liquidity.

**【Business Development & Strategy】**
- 3-pronged growth strategy: maximize existing customers, advance pipeline, and expand new business.
- 10 late-stage pipeline programs with potential for commercial approval by 2028.
- Expanded BD pipeline to 50+ opportunities, with 30% targeting large multinationals.
- Customer praise for supply chain support: "Lifecore's support is a strength of our business."

**【Q&A Key Takeaways】**
- **Nirsum Deal Potential**: Phase II to III transition could lead to commercial volumes, with discussions ongoing.
- **Customer Feedback**: Pharma companies prioritizing site transfers and late-stage manufacturing partners.
- **Gross Margin Outlook**: Q2 gross margin improvement (34% vs. Q1 30%) expected to trend higher with scale.
- **Debt Position**: Total debt $160M post PIPE, with improved BMO terms reducing interest costs.
- **Sales Cycle Insights**: 6-18 months for large deals, with education on expanded capabilities needed.


Lifecore Biomedical (LFCR)-2 Jan 25-2025 Q2 Earnings call transcript

- **Revenue Surge**: Q3 2025 revenue up 26% YoY to $31.1 million, driven by HA manufacturing and new customer wins.
- **Profitability Turnaround**: Adjusted EBITDA turns positive at $3.1 million (vs. -$1.8 million YoY), with 17% margin target for Q4.
- **Strategic Wins**: Secured two new customers post-quarter end, including a large pharma site transfer with 2-3 year timeline.
- **Growth Catalysts**: 2027 inflection point with largest customer, 11 late-stage pipeline programs, and 25%+ EBITDA margin target.
- **Operational Excellence**: 20% workforce reduction with no volume impact, new ERP system to enhance efficiency in Q1 2026.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue of $31.1 million, up 26% YoY, driven by increased demand from key customers and new business wins.
- **EBITDA Turnaround**: Adjusted EBITDA improved to $3.1 million (from -$1.8 million YoY), reflecting cost control and operational efficiency.
- **Customer Wins**: Signed two new customers during Q3 and two post-quarter end, including a large pharma company for a commercial site transfer.
- **Pipeline Momentum**: 11 late-stage pipeline programs with potential launches 2026-2029; expects 50% conversion rate for mid-term growth.
- **2027 Inflection Point**: Largest customer to double aseptic fill/finish demand, with HA qualified for Japanese market.
- **Operational Efficiency**: 20% workforce reduction over 18 months with no volume impact, targeting 25%+ EBITDA margin.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: $4.8 million increase in HA manufacturing (20% YoY), $1.6 million in CDMO (6% YoY growth).
- **Gross Profit**: $7.8 million (vs. $5.4 million YoY), driven by HA volume growth and CDMO margin stabilization.
- **Cost Control**: SG&A down 36% YoY to $8.9 million, with $5.9 million reduction in legacy and recurring expenses.
- **Transition Period Guidance**: Q4 2025 revenue $34-36 million (8% YoY growth), adjusted EBITDA $7-9 million (17% margin).

**【Q&A Key Highlights】**
- **Stub Period Growth**: Q4 2025 revenue expected to grow 20% YoY, driven by customer ordering patterns and new business.
- **Commercial Site Transfer**: New large pharma customer contract to take 24-30 months, with potential to become top 5 customer.
- **Margin Expansion**: Targeting 17% EBITDA margin in Q4 2025, up from 10% in Q3, via revenue growth and cost efficiency.
- **Pipeline Visibility**: GLP-1 program progressing, with Phase III batches completed and validation batches expected Q1 2026.
- **2026 Outlook**: Back-half stronger than front-half, with 55% of revenue in Q3/Q4 vs. 45% in Q1/Q2.

LFCR

LFCR fundamentals

Earnings Call

You can ask Aime